Key facts, as of
As of November 4, 2026, Moderna Inc. (MRNA) trades at $248.36, up 945.7% over the past year. Its 52-week range runs from $22.28 to $254.48; the price is 2.4% below that high. It is 50.1% below its all-time high of $497.49, reached in August 2021. It sits 177.7% above its 200-day average of $89.45, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 101.3% annualized, which we rate very high risk. Moderna Inc. (MRNA) has confirmed its next earnings report for November 6, 2026, before the market opens (date from Yahoo Finance, listed on our November 2026 earnings calendar).
Cite: Portfolio Terminal, "Moderna Inc. (MRNA) stock analysis", 2026-11-04. https://portfolio-terminal.com/analyse/mrna
Where it trades today
trading 97% of the way up its 52-week range
How the price has moved
How far it is from its record
Moderna Inc. (MRNA) is 50.1% below its all-time high of $497.49, reached in August 2021.
The read, from its own figures
What its numbers say
- MRNA closes above its 50-day average ($187.58), and the 50-day sits above the 200-day ($89.45): on both averages the chart reads as an uptrend.
- At $248.36, MRNA is 2.4% below its 1-year high of $254.48, set on October 21, 2026, and 1014.7% above its 1-year low of $22.28 (November 21, 2025).
- Over the past month MRNA rose 22.2%, from $203.21 to $248.36.
- MRNA's 30-day volatility, 101.3% a year, works out to a typical daily move of about 6.4%.
- Yahoo Finance puts its beta at 1.17: over five years of monthly returns, MRNA moved about 1.17% for each 1% move of the S&P 500.
- The last session traded 0.3x MRNA's average daily volume of the 30 sessions before it.
What would change the read
- A close under the 50-day average, $187.58 (−24.5% from the last close), would turn the read to a pullback; under the 200-day, $89.45 (−64.0%), the longer rise is in question.
- A close above $254.48 (+2.5%) would be a new 1-year high; below $22.28 (−91.0%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for MRNA, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under biotechnology among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for MRNA by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for MRNA. Last refresh: Nov 4, 2026, 3:42 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Biotechnology.
What Moderna Inc. does
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products,…
What analysts expect
MRNA carries a hold consensus from 19 analysts, with an average price target of $138.37 versus $248.36 today (-44.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
MRNA generated $2.23B in trailing revenue (2.1% year over year), with a -141.4% net margin, and $299.25M of free cash flow, supported by $3.85B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $1.92B | $1.05B | -$3.07B | -$2.82B | -$7.26 | -$2.08B |
| 2024 | $3.20B | $1.74B | -$3.94B | -$3.56B | -$9.28 | -$4.05B |
| 2023 | $6.75B | $2.06B | -$4.24B | -$4.71B | -$12.33 | -$3.83B |
| 2022 | $18.88B | $13.46B | $9.42B | $8.36B | $21.26 | $4.58B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
MRNA is in 17 of the 54 ETFs we track. It weighs most in XLV: 1.26% of the fund, holding #20 of 62. It is RSP's largest holding.
How its figures compare with those peers
Companies in the same industry
MRNA beside the other companies Yahoo Finance files under biotechnology among the assets we track (VRTX, REGN, INCY, largest first).
MRNAyou are here$248.36$99.15B
VRTXVertex Pharmaceuticals$534.86$135.57B
REGNRegeneron Pharmaceuticals$949.76$98.25B
INCYIncyte Corporation$118.97$24.25BWhat the chart is saying
In an uptrend, 2.4% under its 1-year high with no resistance above.
uptrend- Price is 32.4% above its 50-day average and 177.7% above its 200-day.
- RSI at 66 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $179.56 (-27.7%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
What is the risk level of MRNA?
Based on 30-day volatility of 101.3%, MRNA has VERY HIGH risk. Its beta of 1.17 means it has swung more than the S&P 500 over the last five years.
Does MRNA pay dividends?
Yahoo Finance shows no dividend yield for Moderna Inc. (November 4, 2026).
How far is MRNA from its all-time high?
Moderna Inc. is 50.1% below its all-time high of $497.49, reached in August 2021.
When does Moderna Inc. report earnings?
Moderna Inc. (MRNA) reports its next quarterly earnings on Friday, November 6, 2026, before the market opens. The company has confirmed the date; it comes from Yahoo Finance's earnings data and is listed on the Portfolio Terminal November 2026 earnings calendar. For that quarter, the analysts' consensus Yahoo Finance reports is a loss of $1.35 per share.
Which ETFs hold MRNA?
17 of the 54 popular ETFs we track hold Moderna Inc.. The largest weights: XLV (1.26%), VB (0.44%), QQQM (0.38%), QQQ (0.38%) and CNDX (0.38%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is MRNA?
0.11%, as of September 30, 2026: MRNA is holding #160 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $1.09 in Moderna Inc..
What is the analyst price target for MRNA?
The average analyst price target for Moderna Inc. (MRNA) is $138.37 based on 19 analyst estimates, about 44.3% below the current price of $248.36. The published range runs from $45.00 to $251.00.
How much revenue does MRNA generate?
Moderna Inc. reported $2.23B in trailing twelve-month revenue. Revenue growth is running at 2.1% year over year. Net margin sits at -141.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare MRNA with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.